Table 1.
Clinical characteristics of patients with MM.
| Characteristics | Patient number of sequencing (n = 10) | Patient number of gene chip detection (n = 10) |
|---|---|---|
| Age (year) ≧60 | 6 (60%) | 6 (60%) |
| Sex | ||
| Male | 6 (60%) | 8 (80%) |
| Female | 4 (40%) | 2 (20%) |
| Immunoglobulin type | ||
| IgA | 2 (20%) | 3 (30%) |
| IgG | 7 (70%) | 1 (10%) |
| Light chain type | 1 (10%) | 4 (40%) |
| International Staging System (ISS) at diagnosis | ||
| Durie-Salmon (DS) stage | ||
| I | 1 (10%) | 1 (10%) |
| II | 2 (20%) | 1 (10%) |
| III | 7 (70%) | 8 (80%) |
| ISS stage | ||
| I | 1 (10%) | 2 (20%) |
| II | 2 (20%) | 2 (20%) |
| III | 7 (70%) | 6 (60%) |
| Complicated with nephropathy | 2 (20%) | 4 (40%) |
| Complicated with extramedullary lesions | 1 (10%) | 0 (0%) |
| Cytogenetics/FISH | ||
| Standard risk | 3 (30%) | 2 (20%) |
| High risk: del(17p), t(4;14), t(14;16), 1q21 | 7 (70%) | 8 (80%) |
MM, multiple myeloma; FISH, fluorescence in situ hybridization.